PMLiVE3mon
Committee for Medicinal Products for Human Use (CHMP)
The Committee is responsible for preparing the European Medicines Agency’s (EMA) opinions on all questions concerning medicinal products for human use, in accordance with Regulation (EC) No 726/2004.
Medscape5d
EMA to Review New Safety Data on Alzheimer’s Drug Leqembi
The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.
GlobalData on MSN4mon
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPA
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approving ...
AstraZeneca’s Imfinzi recommended for approval in EU by CHMP
Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...
Hosted on MSN1mon
EMA CHMP recommends Lilly’s Crohn’s therapy for EU approval
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Omvoh (mirikizumab) for approval in the European Union (EU) to treat ...
pharmaphorum21d
Takeda dengue vaccine receives positive CHMP opinion
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Takeda GmbH’s live, attenuated dengue tetravalent vaccine, Qdenga (TAK ...
X4 Pharmaceuticals announces EMA validation of MAA for mavorixafor
X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...